Shandong Luoxin Pharmaceutical Group Co., Ltd. was recognized as a "National Key High-tech Enterprise" by the Ministry of Science and Technology. The company has more than 30 production lines for powder injections, freeze-dried powder injections, water injections, solid preparations, chemical APIs, cephalosporin APIs, and oral cephalosporin series products. At present, there are more than a dozen dosage forms and more than 310 product specifications on the market, including 41 national-level new drugs, cephalosporins and other series of products, forming a one-stop production scale from the synthesis of starting raw materials to the preparation and packaging of finished products. It can produce 1 billion powder injections, 300 million freeze-dried powder injections, 500 million water injections, 2.5 billion tablets, 2 billion capsules, 300 million bags of granules, 80 million bags of dry suspensions, and cephalosporins annually. 300 tons of bacteriocin APIs and 100 tons of other chemical APIs.
The company adheres to the strategy of "revitalizing the enterprise through science and technology" and actively cooperates with major universities and scientific research institutions across the country. With Shenyang Pharmaceutical University as its scientific research support, the company has established the "Shenyang Pharmaceutical University Luoxin Pharmaceutical Postdoctoral Fellowship" "Mobile Workstation", "Shenyang Pharmaceutical University Luoxin Pharmaceutical Teaching and Training Base", "Shenyang Pharmaceutical University Luoxin Pharmaceutical Internship Base", "Shenyang Pharmaceutical University Luoxin Pharmaceutical Graduates Employment Base". The company's product Jinxin was included in the 2011 subject of the National "Major New Drug Creation" Science and Technology Major "Twelfth Five-Year Plan" Implementation Plan - Technical Transformation of Large Variety of Drugs, and the company's "Cefizopran Hydrochloride API and Injection" project was included in the 2010 Annual Shandong Province Torch Program. In 2010, the company was recognized as the "National Comprehensive New Drug R&D Technology Platform (Shandong) Industrialization Demonstration Enterprise", "The Second Batch of Innovative Pilot Enterprises in Shandong Province", "China Patented Shandong Star Enterprise", and has established a Shandong Province Freeze Dry powder injection drug engineering technology research center, provincial enterprise technology center. After review by the Ministry of Human Resources and Social Security and the National Postdoctoral Management Committee, the company was approved to establish a national postdoctoral research station, which provides a new way for the company to cultivate, attract and use high-level professional and technical talents, enhance research and development capabilities, and promote the construction of an innovation system. Wide spaces.
The company actively implements the strategy of using technology to create product brands, using famous brand products to increase corporate visibility, and using corporate visibility to drive product sales, laying a solid stamina and foundation for corporate development. In order to speed up the implementation of scientific and technological innovation, the company has increased its investment in science and technology and withdraws 5% of sales revenue as scientific research funds every year to speed up the implementation of scientific and technological innovation. The company is accelerating the implementation of more than 30 scientific research projects and more than 20 clinical verification projects. Among them, there are several new Class I drugs with independent intellectual property rights that have been implemented in preclinical and clinical trials. The company attaches great importance to the training and construction of a team of scientific and technological talents, and currently has 151 full-time scientific and technological talents, including 6 with doctorate degrees and 28 with master's degrees.
Luoxin Pharmaceutical’s various economic indicators rank at the forefront of the same industry, and it has achieved good economic and social benefits. Many of its products have won the "Science and Technology Progress Award", and the traditional Chinese medicine freeze-dried powder for injection Forskolin 22 other products have obtained national invention patent certificates, with patent protection for 20 years. The company has been rated as an "AAA①" integrity enterprise by the Ministry of Commerce. The "Luoxin" trademark has been recognized as a "China's Well-known Trademark" by the Trademark Office of the State Administration for Industry and Commerce. It has been awarded honorary titles such as "AAA-level credibility enterprise", "contract-abiding and credit-abiding enterprise", "civilized unit", and "advanced unit in the pharmaceutical industry" by the province and city. Since 2006, the company has continuously entered the top 100 enterprises in China's pharmaceutical industry and the top ten most growing pharmaceutical companies in China. Luoxin Pharmaceutical's market network has spread rapidly across the country. It has self-operated import and export rights. Its stocks have been listed in Hong Kong in 2005. It has also taken a gratifying step in the development of foreign markets, bringing the company's development into a new stage. New mileage.